Form 8-K TherapeuticsMD, Inc. For: May 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
TherapeuticsMD (TXMD) PT Raised to $12 at Oppenheimer Following FDA Approval
May 30, 2018 12:26 PM EDTOppenheimer raised its price target on TherapeuticsMD (NASDAQ: TXMD) to $12.00 (from $10.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "TXMD announced FDA approval of Imvexxy (estradiol vaginal inserts) with a label supporting what we view as the best-in-class profile based on safety,... More
